Multiple Sclerosis Market Forecast. With FDA advisory board support for Gilenia (fingolimod), Novartis will move ahead of Merck Serono's oral cladribine in the race to become the first oral multiple sclerosis therapy. These new product launches will see the multiple sclerosis market grow at a compound annual growth rate (CAGR) of 2.3% over the next 10 years. The study reviews the current and future performance of the multiple sclerosis drug class market and covers major commercial opportunities and threats ...
<shortened url>
i guess ccsvi is a"threat"
Multiple Sclerosis Market Forecast
-
- Similar Topics
- Replies
- Views
- Last post
-
- 0 Replies
- 1659 Views
-
Last post by frodo
-
- 0 Replies
- 1710 Views
-
Last post by frodo
-
- 1 Replies
- 1856 Views
-
Last post by frodo
-
- 0 Replies
- 1835 Views
-
Last post by frodo
-
- 0 Replies
- 3660 Views
-
Last post by frodo
-
- 0 Replies
- 2274 Views
-
Last post by frodo
-
- 0 Replies
- 1908 Views
-
Last post by NHE
-
- 0 Replies
- 1331 Views
-
Last post by frodo
-
- 0 Replies
- 1505 Views
-
Last post by frodo